The Effect of Low-Calorie diet rich in whole grains and legumes on Obese Women with Hedonic Eating Behaviors

The effects of low-calorie diet rich in whole grains and legumes on appetite control, improvement of hedonic eating behavior, lipid and glycemic profile, Serum levels of serotonin and insulin and hs-CRP in Obese women with hedonic eating behavior

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190819044563N2

Enrollment

Registered

2020-03-21

Start date

2019-11-11

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Obesity due to excess calories

Interventions

Intervention 1: Intervention group: Low-calorie diet (500kg reduction per person daily requirement) plus at least 4 whole grains and 3 legumes per day for three months. Intervention 2: Control group:

Eligibility

Sex/Gender

Female

Age

19 Years to 45 Years

Inclusion criteria

Inclusion criteria: Individuals with BMI =25 Hedonic eating behavior

Exclusion criteria

Exclusion criteria: Chronic diseases such as diabetes and coronary heart disease Cancer smoking Uncontrolled High Blood Pressure (above 100/160 mmHg) Pregnancy and lactation Use of antibiotic drugs for 3 months Digestive tract diseases Autoimmune disease Use of immunosuppressants Taking medication for dyslipidemia Use of medications that affect metabolism, blood sugar, appetite and food intake Taking non-steroidal anti-inflammatory drugs Observe a specific diet Take a diet to lose weight

Design outcomes

Primary

Measure	Time frame
Triglyceride. Timepoint: Blood triglyceride levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum triglyceride concentration measurement by enzymatic method with BT1500.;High-density lipoprotein. Timepoint: Blood High-density lipoprotein levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum high-density lipoprotein concentration measurement by enzymatic method with BT1500.;Low-density lipoprotein. Timepoint: Blood Low-density lipoprotein levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum low-density lipoprotein concentration measurement by enzymatic method with BT1500.;Fasting blood sugar. Timepoint: Blood Fasting blood sugar levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum fasting blood sugar concentration measurement by enzymatic method of glucose oxidase with BT1500.;Total cholesterol. Timepoint: Blood Total cholesterol levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum total cholesterol concentration measurement by enzymatic method with BT1500.;C-reactive protein. Timepoint: Blood C-reactive protein levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum total cholesterol concentration measurement by enzymatic method with BT1500.;Appetite. Timepoint: In the first weeks, 6 and 12 study and each day for 3 days at noon meal (before eating the main meal and after eating for 3 hours will be filled as 1 hour, 2 hours and 3 hours after meal). Method of measurement: Visual Analogue Scale.;Hedonic eating behavior. Timepoint: The first week and 12 studies were assessed using a questionnaire. Method of measurement: Using the Power of Food Scale Questionnaire.;Insulin. Timepoint: Blood Insulin levels at baseline (before intervention)	—

Measure

Time frame

Triglyceride. Timepoint: Blood triglyceride levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum triglyceride concentration measurement by enzymatic method with BT1500.;High-density lipoprotein. Timepoint: Blood High-density lipoprotein levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum high-density lipoprotein concentration measurement by enzymatic method with BT1500.;Low-density lipoprotein. Timepoint: Blood Low-density lipoprotein levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum low-density lipoprotein concentration measurement by enzymatic method with BT1500.;Fasting blood sugar. Timepoint: Blood Fasting blood sugar levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum fasting blood sugar concentration measurement by enzymatic method of glucose oxidase with BT1500.;Total cholesterol. Timepoint: Blood Total cholesterol levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum total cholesterol concentration measurement by enzymatic method with BT1500.;C-reactive protein. Timepoint: Blood C-reactive protein levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum total cholesterol concentration measurement by enzymatic method with BT1500.;Appetite. Timepoint: In the first weeks, 6 and 12 study and each day for 3 days at noon meal (before eating the main meal and after eating for 3 hours will be filled as 1 hour, 2 hours and 3 hours after meal). Method of measurement: Visual Analogue Scale.;Hedonic eating behavior. Timepoint: The first week and 12 studies were assessed using a questionnaire. Method of measurement: Using the Power of Food Scale Questionnaire.;Insulin. Timepoint: Blood Insulin levels at baseline (before intervention)

—

Secondary

Measure	Time frame
Weight. Timepoint: Weight measurement at baseline (before intervention) and at 1, 6 and 12 weeks. Method of measurement: The weight of a person with minimal clothing and no shoes is measured to the nearest with BIA.;Physical activity. Timepoint: Physical activity measurement at baseline (before intervention) and at 1, 6 and 12 weeks. Method of measurement: Measurement of physical activity at three levels of light, moderate and vigorous using the International Physical Activity Questionnaire.;Systolic blood pressure. Timepoint: Systolic blood pressure measurement at baseline (before intervention) and at 1 and 12 weeks. Method of measurement: Using a calibrated digital barometer.;Diastolic blood pressure. Timepoint: Diastolic blood pressure measurement at baseline (before intervention) and at 1 and 12 weeks. Method of measurement: Using a calibrated digital barometer.;Height. Timepoint: Measurement of individuals height at baseline (before intervention). Method of measurement: Using BIA.	—

Measure

Time frame

Weight. Timepoint: Weight measurement at baseline (before intervention) and at 1, 6 and 12 weeks. Method of measurement: The weight of a person with minimal clothing and no shoes is measured to the nearest with BIA.;Physical activity. Timepoint: Physical activity measurement at baseline (before intervention) and at 1, 6 and 12 weeks. Method of measurement: Measurement of physical activity at three levels of light, moderate and vigorous using the International Physical Activity Questionnaire.;Systolic blood pressure. Timepoint: Systolic blood pressure measurement at baseline (before intervention) and at 1 and 12 weeks. Method of measurement: Using a calibrated digital barometer.;Diastolic blood pressure. Timepoint: Diastolic blood pressure measurement at baseline (before intervention) and at 1 and 12 weeks. Method of measurement: Using a calibrated digital barometer.;Height. Timepoint: Measurement of individuals height at baseline (before intervention). Method of measurement: Using BIA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAsma Zamanian

Oroumia University of Medical Sciences

asma_wzm@yahoo.com+98 44 3223 4897

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026